{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:42:36Z","timestamp":1790995356261,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to assess the efficacy and safety of 2 Janus kinase (JAK) inhibitors (jakinibs) tofacitinib and ruxolitinib in the treatment of type I interferonopathies patients including STING-associated vasculopathy with onset in infancy (SAVI), Aicardi-Gouti\u00e8res syndrome (AGS), and spondyloenchondrodysplasia with immune dysregulation (SPENCD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 6 patients were considered in this study: 2 patients with SAVI, 1 patient with AGS1, 1 patient with AGS7, and 2 patients with SPENCD. Clinical manifestations, laboratory investigations, radiology examinations, treatment, and outcomes were collected between November 2017 and November 2021 in Peking Union Medical College Hospital. The disease score for patients with SAVI and AGS scale for patients with AGS were documented. The expression of 6 interferon-stimulated genes (ISGs) was assessed by real-time PCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three patients (1 patient with SAVI, 2 patients with AGS) were treated with ruxolitinib and 3 patients (1 patient with SAVI, 2 patients with SPENCD) were treated with tofacitinib. The mean duration of the treatment was 2.5\u00a0years (1.25\u20134\u00a0years). Upon treatment, cutaneous lesions and febrile attacks subsided in all affected patients. Two patients discontinued the corticoid treatment. Two patients with SAVI showed an improvement in the disease scores (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05). The erythrocyte sedimentation rate normalized in 2 patients with AGS. The interferon score (IS) was remarkably decreased in 2 patients with SPENCD (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.01). Catch-ups with growth and weight gain were observed in 3 and 2 patients, respectively. Lung lesions improved in 1 patient with SAVI and remained stable in 3 patients. Lymphopenia was found in 3 patients during the treatment without severe infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The JAK inhibitors baricitinib and tofacitinib are promising therapeutic agents for patients with SAVI, AGS, and SPENCD, especially for the improvement of cutaneous lesions and febrile attacks. However, further cohort studies are needed to assess the efficacy and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.825367","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T16:39:40Z","timestamp":1648571980000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China"],"prefix":"10.3389","volume":"13","author":[{"given":"Wendao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingran","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiying","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingsheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06220.x","article-title":"Type I Interferonopathies: A Novel Set of Inborn Errors of Immunity","volume":"1238","author":"Crow","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev-med-050715-104506","article-title":"The Type I Interferonopathies","volume":"68","author":"Lee-Kirsch","year":"2017","journal-title":"Annu Rev Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041257","article-title":"Self-Awareness: Nucleic Acid-Driven Inflammation and the Type I Interferonopathies","volume":"37","author":"Uggenti","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.631329","article-title":"Type I Interferonopathies in Children: An Overview","volume":"9","author":"d'Angelo","year":"2021","journal-title":"Front Pediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214037","article-title":"Efficacy of JAK1\/2 Inhibition in the Treatment of Chilblain Lupus Due to TREX1 Deficiency","volume":"78","author":"Briand","year":"2019","journal-title":"Ann Rheumatic Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00645-0","article-title":"Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome","volume":"39","author":"Volpi","year":"2019","journal-title":"J Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901477","article-title":"Translating JAKs to Jakinibs","volume":"204","author":"Gadina","year":"2020","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.07.028","article-title":"JAK Inhibition in the Type I Interferonopathies","volume":"148","author":"Crow","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.07.015","article-title":"Efficacy of the Janus Kinase 1\/2 Inhibitor Ruxolitinib in the Treatment of Vasculopathy Associated With TMEM173-Activating Mutations in 3 Children","volume":"138","author":"Fremond","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2001362","article-title":"Janus Kinase Inhibition in the Aicardi-Goutieres Syndrome","volume":"383","author":"Vanderver","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0359-1","article-title":"Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease","volume":"37","author":"Rice","year":"2017","journal-title":"J Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1673-5501.2021.01.005","article-title":"A Case of Aicardi-Goutieres Syndrome Type 7 in China and Literature Review","volume":"16","author":"Wang","year":"2021","journal-title":"Chin J Evid Based Pediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2014.10.005","article-title":"Type I Interferonopathies: Mendelian Type I Interferon Up-Regulation","volume":"32","author":"Crow","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41577-021-00633-9","article-title":"The Type I Interferonopathies: 10 Years on","volume":"20","author":"Crow","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 Inhibition With Baricitinib in the Treatment of Autoinflammatory Interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00690-9","article-title":"STING-Associated Vasculopathy With Onset in Infancy in Three Children With New Clinical Aspect and Unsatisfactory Therapeutic Responses to Tofacitinib","volume":"40","author":"Tang","year":"2020","journal-title":"J Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jaip.2020.11.007","article-title":"Overview of STING-Associated Vasculopathy With Onset in Infancy (SAVI) Among 21 Patients","volume":"9","author":"Fremond","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209841","article-title":"Familial Chilblain Lupus Due to a Gain-of-Function Mutation in STING","volume":"76","author":"Konig","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01535","article-title":"A Mutation Outside the Dimerization Domain Causing Atypical STING-Associated Vasculopathy With Onset in Infancy","volume":"9","author":"Saldanha","year":"2018","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex316","article-title":"Type I Interferonopathy in a Young Adult","volume":"56","author":"Manoussakis","year":"2017","journal-title":"Rheumatol (Oxford England)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031081","article-title":"JAK Inhibition in the Aicardi\u2013Gouti\u00e8res Syndrome","volume":"383","author":"Neven","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004921","article-title":"An Open-Label Trial of JAK 1\/2 Blockade in Progressive IFIH1-Associated Neuroinflammation","volume":"90","author":"Kothur","year":"2018","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa356","article-title":"Successful Treatment of Spondyloenchondrodysplasia With Baricitinib","volume":"60","author":"Shimizu","year":"2021","journal-title":"Rheumatol (Oxford England)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK Inhibition as a Therapeutic Strategy for Immune and Inflammatory Diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0430-0","article-title":"Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster","volume":"39","author":"Yamaoka","year":"2016","journal-title":"Drug Saf"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1810983","article-title":"Reverse-Transcriptase Inhibitors in the Aicardi-Goutieres Syndrome","volume":"379","author":"Rice","year":"2018","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.03.010","article-title":"Successful Treatment of a Novel Type I Interferonopathy Due to a De Novo PSMB9 Gene Mutation With a Janus Kinase Inhibitor","volume":"148","author":"Kataoka","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.825367\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T16:39:43Z","timestamp":1648571983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.825367\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2022.825367"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.825367","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"article-number":"825367"}}